Your browser doesn't support javascript.
loading
Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches.
Asadinezhad, Maryam; Khoshnood, Saeed; Asadollahi, Parisa; Ghafourian, Sobhan; Sadeghifard, Nourkhoda; Pakzad, Iraj; Zeinivand, Yasaman; Omidi, Nazanin; Hematian, Ali; Kalani, Behrooz Sadeghi.
Affiliation
  • Asadinezhad M; Students Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
  • Khoshnood S; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
  • Asadollahi P; Students Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
  • Ghafourian S; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
  • Sadeghifard N; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
  • Pakzad I; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
  • Zeinivand Y; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
  • Omidi N; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
  • Hematian A; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
  • Kalani BS; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Brief Bioinform ; 25(1)2023 11 22.
Article in En | MEDLINE | ID: mdl-38189537
ABSTRACT
The rising issue of antibiotic resistance has made treating Pseudomonas aeruginosa infections increasingly challenging. Therefore, vaccines have emerged as a viable alternative to antibiotics for preventing P. aeruginosa infections in susceptible individuals. With its superior accuracy, high efficiency in stimulating cellular and humoral immune responses, and low cost, mRNA vaccine technology is quickly replacing traditional methods. This study aimed to design a novel mRNA vaccine by using in silico approaches against P. aeruginosa. The research team identified five surface and antigenic proteins and selected their appropriate epitopes with immunoinformatic tools. These epitopes were then examined for toxicity, allergenicity and homology. The researchers also checked their presentation and identification by major histocompatibility complex cells and other immune cells through valuable tools like molecular docking. They subsequently modeled a multi-epitope protein and optimized it. The mRNA was analyzed in terms of structure and stability, after which the immune system's response against the new vaccine was simulated. The results indicated that the designed mRNA construct could be an effective and promising vaccine that requires laboratory and clinical trials.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pseudomonas Infections / MRNA Vaccines Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Pseudomonas Infections / MRNA Vaccines Limits: Humans Language: En Year: 2023 Type: Article